Table 2.
Intra-hospital management and outcomes according to MPI
| MPI-1 n = 114 |
MPI-2 n = 108 |
MPI-3 n = 19 |
p | |
|---|---|---|---|---|
| Clinical presentation | ||||
| STEMI, n (%) | 73 (64) | 59 (54.6) | 7 (36.8) | 0.058 |
| NSTEMI, n (%) | 41 (36) | 49 (45.4) | 12 (63.2) | 0.058 |
| In-hospital stay | ||||
| Length of in-hospital stay (days), median (IQR) | 6 (5–9) | 7 (6–11) | 9 (5–18) | 0.035* |
| Length of intensive-care stay (days), median (IQR) | 4 (3–5) | 4 (3–5) | 3 (2–5) | 0.659 |
| Laboratory tests | ||||
| TnI-hs (ng/l), median (IQR) | 24,026.6 (45,231.0–74,755.6) | 22,728.5 (50,926.9–92,527.6) | 15,846.6 (23,925–173,674) | 0.985 |
| CK (UI/L), median (IQR) | 649.5 (1093.6–1788.0) | 566.5 (991.1–1789.4) | 550 (399.3–2299.9) | 0.718 |
| CK-MB (ng/ml), median (IQR) | 76.45 (106.43–166.11) | 59.6 (99.24–159.09) | 48.3 (40.66–215.53) | 0.829 |
| Myoglobin (ng/ml), median (IQR) | 326 (822.0–1744.8) | 458.5 (958.7–1886.0) | 477 (574.12–2448.1) | 0.235 |
| Procedural data | ||||
| P-PCI, n (%) | 70 (95.9) | 55 (93.2) | 6 (85.7) | 0.492 |
| Rescue-PCI, n (%) | 3 (4.1) | 4 (6.8) | 1 (14.3) | 0.492 |
| Atrioventricular block, n (%) | 4 (3.5) | 10 (9.3) | 0 (0.0) | 0.099 |
| Temporary pacemaker, n (%) | 3 (2.6) | 6 (5.6) | 0 (0.0) | 0.347 |
| IABP, n (%) | 2 (1.8) | 6 (5.6) | 1 (5.3) | 0.307 |
| In-hospital complications | ||||
| Death, n (%) | 0 (0.0) | 3 (2.8) | 2 (10.5) | 0.009* |
| Cardiogenic shock, n (%) | 1 (0.9) | 8 (7.4) | 1 (5.3) | 0.048* |
| Acute pulmonary oedema, n (%) | 9 (7.9) | 14 (13) | 6 (31.6) | 0.012* |
| NSVT, n (%) | 71 (62.3) | 75 (69.4) | 13 (68.4) | 0.516 |
| VF, n (%) | 9 (7.9) | 3 (2.8) | 1 (5.3) | 0.241 |
| Atrial fibrillation/flutter, n (%) | 11 (9.6) | 28 (25.9) | 7 (36.8) | 0.001* |
| Definitive pacemaker, n (%) | 5 (4.4) | 11 (10.2) | 5 (26.3) | 0.006* |
| Pneumonia, n (%) | 13 (11.4) | 29 (26.9) | 8 (42.1) | 0.001* |
| Heart rupture, n (%) | 0 (0.0) | 3 (2.8) | 2 (10.5) | 0.009* |
| Intrastent thrombosis | 2 (1.8) | 1 (0.9) | 0 (0.0) | 0.752 |
| Pharmacological therapy | ||||
| Diuretics, n (%) | 62 (54.4) | 82 (75.9) | 19 (100) | < 0.001* |
| Cardioaspirin, n (%) | 114 (100) | 107 (99.1) | 18 (94.7) | 0.064 |
| Clopidogrel, n (%) | 42 (36.8) | 65 (60.2) | 16 (84.2) | < 0.001* |
| Others P2Y12 inhibitors, n (%) | 74 (64.9) | 38 (35.2) | 2 (10.5) | < 0.001* |
| Nitrates, n (%) | 9 (7.9) | 14 (13) | 6 (31.6) | 0.012* |
| Oral anticoagulant therapy, n (%) | 12 (10.5) | 28 (25.9) | 11 (57.9) | < 0.001* |
| Antibiotic therapy, n (%) | 24 (21.1) | 42 (38.9) | 10 (52.6) | 0.002* |
*A 2-sided p value <0.05 is considered of statistical significance
STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST segment elevation myocardial infarction, CK creatine kinase, CK-MB creatine kinase myocardial band, TnI-hs high-sensitivity troponin I, PCI percutaneous coronary intervention, PPCI primary percutaneous coronary intervention, IABP intra-aortic balloon pump, NSVT non sustained ventricular tachycardia, VF ventricular fibrillation